Progenics Is A Value Play
The main source of revenue for Progenics (PGNX) currently is the Relistor drug. Relistor is used to treat opioid-induced constipation in chronic non-cancer pain. The global opioid-induced constipation market is estimated to be worth $2779.24 Mn in 2022 with a CAGR of 4.6% during 2016-2022.